<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Dermatol</journal-id><journal-id journal-id-type="publisher-id">IJD</journal-id><journal-title-group><journal-title>Indian Journal of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0019-5154</issn><issn pub-type="epub">1998-3611</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25484410</article-id><article-id pub-id-type="pmc">4248518</article-id><article-id pub-id-type="publisher-id">IJD-59-630b</article-id><article-id pub-id-type="doi">10.4103/0019-5154.143533</article-id><article-categories><subj-group subj-group-type="heading"><subject>E-IJD Original Article</subject></subj-group></article-categories><title-group><article-title>Decreased Vitamin B<sub>12</sub> and Folic Acid Concentrations in Acne Patients After Isotretinoin Therapy: A Controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>G&#x000f6;kalp</surname><given-names>Hilal</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Bulur</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;rer</surname><given-names>MA</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1"><italic>From the Department of Dermatology, Malatya Government Hospital, Malatya, Turkey</italic></aff><aff id="aff2"><label>1</label><italic>Department of Dermatology, Ahi Evran University, Faculty of Medicine, K&#x00131;r&#x0015f;ehir, Turkey</italic></aff><aff id="aff3"><label>2</label><italic>Department of Dermatology, Gazi University, Faculty of Medicine, Ankara, Turkey</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence:</bold> Dr. Hilal G&#x000f6;kalp, Department of Dermatology, Malatya Government Hospital, 44300, Malatya, Turkey. E-mail: <email xlink:href="hilalgklp@gmail.com">hilalgklp@gmail.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2014</year></pub-date><volume>59</volume><issue>6</issue><fpage seq="b">630</fpage><lpage>630</lpage><history><date date-type="received"><month>6</month><year>2013</year></date><date date-type="accepted"><month>7</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Dermatology</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Oral isotretinoin treatment might influence the levels of vitamin B<sub>12</sub> and folic acid.</p></sec><sec id="st2"><title>Aims and Objectives:</title><p>The aim of this study is to compare vitamin B<sub>12</sub> and folic acid levels in patients with moderate and severe acne vulgaris with those of the healthy control group and to investigate the effect of isotretinoin treatment on these vitamins.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>Patients who completed 6 months of isotretinoin therapy for moderate and severe forms of acne vulgaris and a control group consisting of healthy individuals between February 2011 and March 2012 were included in the study. Before isotretinoin therapy and at 6.- months of the therapy, serum vitamin B<sub>12</sub> and folic acid levels were measured. In the healthy control group, vitamin B<sub>12</sub> and folic acid levels were assessed only once.</p></sec><sec id="st4"><title>Results:</title><p>In total, 120 patients with moderate and severe acne vulgaris who completed 6 months isotretinoin therapy and 100 healthy individuals who constituted the control group were included in the study. Pre-treatment vitamin B<sub>12</sub> values of the patient group were found to be statistically significantly higher (<italic>P</italic> = 0.002), but any statistically significant difference was not detected in folic acid measurements (<italic>P</italic> = 0.566). A statistically significant decrease was detected in post-treatment vitamin B<sub>12</sub> and folic acid levels (<italic>P</italic> &#x0003c; 0.05).</p></sec><sec id="st5"><title>Conclusion:</title><p>Vitamin B<sub>12</sub>/folic acid treatment should be given under medical surveillance before and during isotretinoin therapy. Supplementation of these vitamins should be recommended in cases of their deficiency, so as to decrease the risks of neuropsychiatric and occlusive vascular diseases.</p></sec></abstract><kwd-group><kwd><italic>Acne</italic></kwd><kwd><italic>folic acid</italic></kwd><kwd><italic>isotretinoin</italic></kwd><kwd><italic>vitamin B<sub>12</sub></italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><boxed-text position="float"><p><bold>What was known?</bold></p><p>
<list list-type="order"><list-item><p>Vitamin B<sub>12</sub> and folic acid, with their interrelated metabolism, are important vitamins for the maintenance of various metabolic pathways in the body.</p></list-item><list-item><p>Various vitamin supplements, most prominently vitamin B<sub>12</sub>, could exacerbate existing acne and/or cause the development of acneiform eruptions.</p></list-item><list-item><p>Recent studies have suggested that isotretinoin might influence the metabolism of vitamin B<sub>12</sub> and folic acid.</p></list-item></list>
</p></boxed-text><p>Acne vulgaris is the most prevalent skin disease, affecting 83-95% of the adolescent population.[<xref rid="ref1" ref-type="bibr">1</xref>] For many years, the relationship between diet and acne has been investigated. More rapid development of acne in individuals consuming a diet with a higher glycemic index has been suggested.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] It has also been reported that various vitamin supplements, most prominently vitamin B<sub>12</sub> (cyanocobalamin), could exacerbate existing acne and/or cause the development of acneiform eruptions.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] However, recent studies have demonstrated that oral isotretinoin (ISO) treatment, which is effective against the major etiological factors involved in the pathogenesis of acne, might lead to decreases in the levels of vitamin B<sub>12</sub> and folic acid.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Thus, contrary opinions regarding the need for vitamin supplements in patients on ISO treatment have been proposed.[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Vitamin B<sub>12</sub> and folic acid, with their interrelated metabolism, are important for the maintenance of various metabolic pathways in the body. In cases of deficiency, adverse effects on cardiovascular, neurological, psychological, hematological, gastrointestinal, locomotor (musculoskeletal) and immunological systems may occur.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>In this study, vitamin B<sub>12</sub> and folic acid levels in patients with moderate and severe acne vulgaris were compared with those of a healthy control group and the effects of ISO treatment on these vitamins were investigated.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title>Study design</title><p>In this study, we prospectively followed 175 patients who underwent isotretinoin treatment for 6 months between February 2011 and March 2012 for moderate (Grade 2) or severe (Grade 3-4) acne vulgaris. Our control group was consisting of 100 healthy individuals during the same time period. Patients were consecutively selected. Among the patient group, 120 patients who completed 6 months of ISO therapy were included in the statistical analysis. Pregnant women, nursing women, smokers, patients with migraine, hyperlipidemia, hypervitaminosis A and systemic diseases (hepatic and renal insufficiency, hypertension and metabolic disease) were excluded. Patients using any medication or vitamin supplement were also excluded. Patients were started on ISO therapy at daily doses of 0.6-1 mg/kg and titrated over 6 months to a cumulative dose of at least 120 mg/kg. In the patient and control groups, blood samples were drawn into blank tubes and then tubes with ethylenediaminetetraacetic acid. Routine biochemical parameters were measured using an autoanalyzer (Abbott c8000), vitamin B<sub>12</sub> and folic acid levels were assessed using a direct chemiluminescence method and for the evaluation of hematological parameters, a blood cell counter system (Abbott cell dyn 3700) was used. Before ISO therapy and at 6 months of therapy, liver function tests and hemograms were evaluated and serum lipid, vitamin B<sub>12</sub> and folic acid levels were measured. In the healthy control group, vitamin B<sub>12</sub> and folic acid levels were assessed only once.</p></sec><sec id="sec2-2"><title>Statistical analysis</title><p>The SPSS (Statistical Package for Social Sciences) software (version 16 for Windows) was used. For descriptive statistical analyses, median, minimal and maximal values were used. Our data does not show normal distribution. Thus, non-parametric tests are performed, using only median values. For comparisons of the patient and control groups, for numerical values, the Mann-Whitney <italic>U</italic>-test and for categorical variables, Chi-squared tests were used. For the comparison of measurements obtained before and after treatment, the Wilcoxon test was used. <italic>P</italic> = 5% was accepted as the cut-off value for statistical significance.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>In total, 120 patients (98 women, 22 men; mean age, 20 years; age range, 18-40 years) with moderate and severe acne vulgaris who completed 6 months of ISO therapy and 100 healthy individuals (79 women, 21 men; mean age, 21 years; age range, 18-40 years), who constituted the control group, were included in the study. No statistically significant difference was detected between the patient and healthy control groups in terms of age or gender of the patients (<italic>P</italic> &#x0003e; 0.05). Pre-treatment vitamin B<sub>12</sub> values in the patient group were statistically significantly higher (<italic>P</italic> &#x0003c; 0.05), but no statistically significant difference was detected in folic acid levels (<italic>P</italic> = 0.566) [<xref ref-type="table" rid="T1">Table 1</xref>]. Pre- and post-treatment vitamin B<sub>12</sub>, folic acid, biochemical parameters and hemoglobin values were compared [<xref ref-type="table" rid="T2">Table 2</xref>]. A statistically significant decrease was detected in post-treatment vitamin B<sub>12</sub> and folic acid levels while a statistically significant increase was noted in post-treatment levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase (GGT), total cholesterol, triglyceride, low-density lipoprotein (LDL) and very LDL (VLDL) (<italic>P</italic> &#x0003c; 0.05). Significant decreases in post-treatment high-density lipoprotein levels were detected (<italic>P</italic> &#x0003c; 0.05) while no statistically significant difference in alkaline phosphatase (<italic>P</italic> = 0.166) or hemoglobin level (<italic>P</italic> = 0.180) was observed.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of pre-treatment vitamin B<sub>12</sub> and folic acid values</p></caption><graphic xlink:href="IJD-59-630b-g001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of pre- and post-treatment biochemical parameters</p></caption><graphic xlink:href="IJD-59-630b-g002"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>In the medical literature, the argument that especially vitamin B<sub>12</sub> supplements exacerbate acne vulgaris has been proposed multiple times.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref9" ref-type="bibr">9</xref>] In our study, higher pre-treatment vitamin B<sub>12</sub> levels, versus the control group, support the assertion that vitamin B<sub>12</sub> plays a role in the etiopathogenesis of acne vulgaris. However, vitamin B<sub>12</sub> and folic acid, with their interrelated metabolism, are important vitamins in various metabolic pathways, including the homocysteine (Hcy) pathway. Vitamin B<sub>12</sub> and folic acid are cofactors of the methyltransferase enzyme and with their deficiency, hyperhomocysteinemia is seen.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] In recent years, hyperhomocysteinemia has been appreciated as an important risk factor for cardiovascular diseases. The idea that an increased plasma Hcy level is an independent risk factor for endothelial dysfunction and coronary artery disease (CAD) has become a current issue.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>] Increased plasma Hcy level is also a risk factor for cerebrovascular and peripheral vascular diseases, in addition to CAD.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] Furthermore, vitamin B<sub>12</sub>, folic acid and related increases in the levels of Hcy have been associated with many neuropsychiatric diseases. These include bipolar disorder, paranoid psychosis, depression, schizophrenia, Alzheimer's disease and Parkinson's disease.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] In addition to these cardiovascular, neurological and psychological effects, Hcy also exerts adverse effects on hematological, gastrointestinal, locomotor (musculoskeletal) and immunological systems.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>ISO is an effective treatment agent, used frequently both at present and over the last 15 years, for the treatment of moderate and severe acne patients, especially those 15-24 years of age.[<xref rid="ref6" ref-type="bibr">6</xref>] Despite its high therapeutic success rates, it also has many side-effects, especially teratogenicity.[<xref rid="ref17" ref-type="bibr">17</xref>] As recent studies have suggested, ISO influences the metabolism of vitamin B<sub>12</sub>, folic acid and Hcy.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] However, this issue remains controversial. In a study of 28 acne patients, Schulpis <italic>et al</italic>. demonstrated increased Hcy values after 45 days of ISO therapy, with no statistically significant difference in vitamin B<sub>12</sub> or folic acid levels.[<xref rid="ref18" ref-type="bibr">18</xref>] In another study of 74 acne patients, after 45 days of ISO therapy, no change was observed in vitamin B<sub>12</sub> or folic acid levels while Hcy levels increased[<xref rid="ref19" ref-type="bibr">19</xref>], as was also reported by Schulpis <italic>et al</italic>.[<xref rid="ref18" ref-type="bibr">18</xref>] In both of these studies, ISO treatment was cut short and it was suggested that the hyperhomocysteinemia seen during ISO therapy, which developed secondary to hepatic dysfunction, was associated with the inhibition of the cystathionine-&#x003b2;-synthase enzyme.[<xref rid="ref18" ref-type="bibr">18</xref>] In another study of 20 young and 20 old healthy individuals, Chanson <italic>et al</italic>. reported that ISO therapy lasting for 28 days decreased folic acid levels without changing Hcy concentrations.[<xref rid="ref6" ref-type="bibr">6</xref>] From another point of view, ISO may induce decreases in vitamin B<sub>12</sub> and folic acid levels, increasing the risk of hyperhomocysteinemia. Indeed, Karadag <italic>et al</italic>. reported that following 4 months ISO treatment of 66 acne patients, vitamin B<sub>12</sub> and folic acid level decreased, while Hcy values increased.[<xref rid="ref7" ref-type="bibr">7</xref>] This study stressed that long-term ISO therapy caused hepatic dysfunction, followed by vitamin B<sub>12</sub> and folic acid deficiencies, due to its cumulative effects, suggesting an important role in Hcy metabolism. Furthermore, many studies have noted that in addition to increasing the lipid profile, hyperhomocysteinemia as a consequence of vitamin B<sub>12</sub> and folic acid deficiency might increase the risk of CAD.[<xref rid="ref7" ref-type="bibr">7</xref>] Therefore, vitamin supplementation has been suggested to prevent any potential deficiency during ISO therapy. However, the mechanism (s) leading to vitamin deficiency during ISO therapy has/have not yet been determined. In our study, 120 patients who received ISO therapy were followed for longer periods (6 months) than in previous reports. In our study, although values were in the normal range, our results were similar to those reported by Karadag <italic>et al</italic>. and statistically significant decreases in vitamin B<sub>12</sub> and folic acid levels were detected. Furthermore, similar to previous studies, compared with baseline values, significant increases in the levels of post-treatment biochemical parameters (serum glutamic-oxaloacetic, serum glutamic-pyruvic transaminase, GGT, cholesterol, LDL, VLDL, triglycerides) were noteworthy.</p><p>Vitamin B<sub>12</sub> and folic acid deficiencies may also be associated with a number of psychiatric diseases.[<xref rid="ref16" ref-type="bibr">16</xref>] These diseases resemble the psychological side-effects that are sometimes seen in ISO therapy.[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref>] Although conclusive information regarding the etiopathogenesis of the psychological side-effects that might emerge during ISO therapy is lacking, the role of retinoic acid receptors and the impact of retinoids that enter the central nervous system on serotonergic neurons, leading to the development of affective disorders, has been suggested.[<xref rid="ref24" ref-type="bibr">24</xref>] However, in studies of the neuropsychiatric side-effects of ISO, no role of vitamin B<sub>12</sub> and folic acid levels has yet been reported. Karadag's investigation and our study have revealed that long-term use of ISO might decrease vitamin B<sub>12</sub> and folic acid levels. Although no study of the mechanism by which ISO induces vitamin B<sub>12</sub> and folic acid deficiency has yet been reported, we suggest that long-term use of ISO might decrease intestinal absorption of vitamin B<sub>12</sub> and folic acid. This should be assessed in future studies.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>Conclusions</title><p>Systemic retinoids have been used for more than 30 years in the treatment of follicular and keratinisation disorders, ichthyosiform dermatosis, cutaneous neoplasias, various systemic cancers and genetic and acquired immune system diseases.[<xref rid="ref25" ref-type="bibr">25</xref>] This study demonstrated that after a 6 months treatment, ISO can result in decreases in vitamin B<sub>12</sub> and folic acid levels. The failure to identify this effect in short-term studies suggests that the cumulative effect of ISO induces decreases in vitamin levels. Thus, especially in patients receiving more than one course of ISO therapy, vitamin B<sub>12</sub>/folic acid decreases and related side-effects might be encountered more frequently.</p><p>Also, as an outcome of our study, we suggest the following. Because vitamin B<sub>12</sub> supplements may cause or exacerbate acne, their unnecessary use should be avoided. Vitamin B<sub>12</sub>/folic acid treatment should be given under medical surveillance before and during ISO therapy. Supplementation of these vitamins should be recommended in cases of their deficiency, so as to decrease the risks of neuropsychiatric and occlusive vascular diseases. These suggestions are not contradictory, but may also not be fully compatible when evaluated in detail.</p><boxed-text position="float"><p><bold>What is new?</bold></p><p>
<list list-type="order"><list-item><p>Higher pre-treatment vitamin B<sub>12</sub> levels, versus the control group, support the assertion that vitamin B<sub>12</sub> plays a role in the etiopathogenesis of acne vulgaris.</p></list-item><list-item><p>Furthermore, this study demonstrated that after a 6 months treatment, isotretinoin can result in decreases in vitamin B<sub>12</sub> and folic acid levels.</p></list-item><list-item><p>Supplementation of vitamin B<sub>12</sub>/folic acid should be recommended in cases of their deficiency in patients under isotretinoin therapy.</p></list-item></list>
</p></boxed-text></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> Nil.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasim</surname><given-names>ZF</given-names></name><name><surname>McKenna</surname><given-names>KE</given-names></name></person-group><article-title>Vitamin B 12 and folate deficiency anaemia associated with isotretinoin treatment for acne</article-title><source>Clin Exp Dermatol</source><year>2006</year><volume>31</volume><fpage>599</fpage><pub-id pub-id-type="pmid">16716177</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnik</surname><given-names>BC</given-names></name></person-group><article-title>Diet in acne: Further evidence for the role of nutrient signalling in acne pathogenesis</article-title><source>Acta Derm Venereol</source><year>2012</year><volume>92</volume><fpage>228</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">22419445</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danby</surname><given-names>FW</given-names></name></person-group><article-title>Nutrition and acne</article-title><source>Clin Dermatol</source><year>2010</year><volume>28</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">21034984</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherertz</surname><given-names>EF</given-names></name></person-group><article-title>Acneiform eruption due to &#x0201c;megadose&#x0201d; vitamins B6 and B<sub>12</sub></article-title><source>Cutis</source><year>1991</year><volume>48</volume><fpage>119</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">1834437</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupr&#x000e9;</surname><given-names>A</given-names></name><name><surname>Albarel</surname><given-names>N</given-names></name><name><surname>Bonafe</surname><given-names>JL</given-names></name><name><surname>Christol</surname><given-names>B</given-names></name><name><surname>Lassere</surname><given-names>J</given-names></name></person-group><article-title>Vitamin B-12 induced acnes</article-title><source>Cutis</source><year>1979</year><volume>24</volume><fpage>210</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">157854</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanson</surname><given-names>A</given-names></name><name><surname>Cardinault</surname><given-names>N</given-names></name><name><surname>Rock</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Souteyrand</surname><given-names>P</given-names></name><name><surname>D&#x02019;Incan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Decreased plasma folate concentration in young and elderly healthy subjects after a short-term supplementation with isotretinoin</article-title><source>J Eur Acad Dermatol Venereol</source><year>2008</year><volume>22</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">18181979</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karadag</surname><given-names>AS</given-names></name><name><surname>Tutal</surname><given-names>E</given-names></name><name><surname>Ertugrul</surname><given-names>DT</given-names></name><name><surname>Akin</surname><given-names>KO</given-names></name></person-group><article-title>Effect of isotretinoin treatment on plasma holotranscobalamin, vitamin B<sub>12</sub>, folic acid, and homocysteine levels: Non-controlled study</article-title><source>Int J Dermatol</source><year>2011</year><volume>50</volume><fpage>1564</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22098008</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>CF</given-names></name></person-group><article-title>Laboratory diagnosis of vitamin B<sub>12</sub> and folate deficiency: A guide for the primary care physician</article-title><source>Arch Intern Med</source><year>1999</year><volume>159</volume><fpage>1289</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10386505</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>T</given-names></name><name><surname>Romiti</surname><given-names>R</given-names></name><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Altmeyer</surname><given-names>P</given-names></name></person-group><article-title>Rosacea fulminans triggered by high-dose vitamins B6 and B 12</article-title><source>J Eur Acad Dermatol Venereol</source><year>2001</year><volume>15</volume><fpage>484</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11763399</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>LL</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Rogers</surname><given-names>K</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Helfand</surname><given-names>M</given-names></name></person-group><article-title>Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><fpage>1203</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18990318</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname><given-names>MB</given-names></name><name><surname>Eshraghian</surname><given-names>K</given-names></name><name><surname>Omrani</surname><given-names>GR</given-names></name><name><surname>Lankarani</surname><given-names>KB</given-names></name><name><surname>Hosseini</surname><given-names>E</given-names></name></person-group><article-title>Homocysteine level and coronary artery disease</article-title><source>Angiology</source><year>2006</year><volume>57</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16444451</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casas</surname><given-names>JP</given-names></name><name><surname>Bautista</surname><given-names>LE</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name></person-group><article-title>Homocysteine and stroke: Evidence on a causal link from mendelian randomisation</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>224</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15652605</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pianka</surname><given-names>P</given-names></name><name><surname>Almog</surname><given-names>Y</given-names></name><name><surname>Man</surname><given-names>O</given-names></name><name><surname>Goldstein</surname><given-names>M</given-names></name><name><surname>Sela</surname><given-names>BA</given-names></name><name><surname>Loewenstein</surname><given-names>A</given-names></name></person-group><article-title>Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>1588</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10919914</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boushey</surname><given-names>CJ</given-names></name><name><surname>Beresford</surname><given-names>SA</given-names></name><name><surname>Omenn</surname><given-names>GS</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name></person-group><article-title>A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes</article-title><source>JAMA</source><year>1995</year><volume>274</volume><fpage>1049</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">7563456</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quadri</surname><given-names>P</given-names></name><name><surname>Fragiacomo</surname><given-names>C</given-names></name><name><surname>Pezzati</surname><given-names>R</given-names></name><name><surname>Zanda</surname><given-names>E</given-names></name><name><surname>Forloni</surname><given-names>G</given-names></name><name><surname>Tettamanti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>80</volume><fpage>114</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15213037</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Durat</surname><given-names>G</given-names></name><name><surname>Atasoy</surname><given-names>I</given-names></name></person-group><article-title>Mental and neurological disorders related to vitamin B 12 and folic acid deficiencies</article-title><source>[Turk Klin Biyokimya Derg]</source><year>2009</year><volume>7</volume><fpage>31</fpage><lpage>6</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zouboulis</surname><given-names>CC</given-names></name><name><surname>Piquero-Martin</surname><given-names>J</given-names></name></person-group><article-title>Update and future of systemic acne treatment</article-title><source>Dermatology</source><year>2003</year><volume>206</volume><fpage>37</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">12566804</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulpis</surname><given-names>KH</given-names></name><name><surname>Karikas</surname><given-names>GA</given-names></name><name><surname>Georgala</surname><given-names>S</given-names></name><name><surname>Michas</surname><given-names>T</given-names></name><name><surname>Tsakiris</surname><given-names>S</given-names></name></person-group><article-title>Elevated plasma homocysteine levels in patients on isotretinoin therapy for cystic acne</article-title><source>Int J Dermatol</source><year>2001</year><volume>40</volume><fpage>33</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11277950</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polat</surname><given-names>M</given-names></name><name><surname>Lenk</surname><given-names>N</given-names></name><name><surname>Bing&#x000f6;l</surname><given-names>S</given-names></name><name><surname>Ozta&#x0015f;</surname><given-names>P</given-names></name><name><surname>Ilhan</surname><given-names>MN</given-names></name><name><surname>Art&#x000fc;z</surname><given-names>F</given-names></name><etal/></person-group><article-title>Plasma homocysteine level is elevated in patients on isotretinoin therapy for cystic acne: A prospective controlled study</article-title><source>J Dermatolog Treat</source><year>2008</year><volume>19</volume><fpage>229</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">18608712</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behnam</surname><given-names>B</given-names></name><name><surname>Taheri</surname><given-names>R</given-names></name><name><surname>Ghorbani</surname><given-names>R</given-names></name><name><surname>Allameh</surname><given-names>P</given-names></name></person-group><article-title>Psychological impairments in the patients with acne</article-title><source>Indian J Dermatol</source><year>2013</year><volume>58</volume><fpage>26</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23372208</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>C</given-names></name><name><surname>Grabarkiewicz</surname><given-names>J</given-names></name><name><surname>Theisen</surname><given-names>FM</given-names></name><name><surname>Remschmidt</surname><given-names>H</given-names></name></person-group><article-title>Isotretinoin, depression and suicide ideation in an adolescent boy</article-title><source>Pharmacopsychiatry</source><year>2007</year><volume>40</volume><fpage>128</fpage><pub-id pub-id-type="pmid">17541889</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marqueling</surname><given-names>AL</given-names></name><name><surname>Zane</surname><given-names>LT</given-names></name></person-group><article-title>Depression and suicidal behavior in acne patients treated with isotretinoin: A systematic review</article-title><source>Semin Cutan Med Surg</source><year>2007</year><volume>26</volume><fpage>210</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">18395669</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaymak</surname><given-names>Y</given-names></name><name><surname>Taner</surname><given-names>E</given-names></name><name><surname>Taner</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents</article-title><source>Int J Dermatol</source><year>2009</year><volume>48</volume><fpage>41</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19126049</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Reilly</surname><given-names>KC</given-names></name><name><surname>Trent</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>SJ</given-names></name><name><surname>Lane</surname><given-names>MA</given-names></name></person-group><article-title>13-cis-Retinoic acid alters intracellular serotonin, increases 5-HT1A receptor, and serotonin reuptake transporter levels <italic>in vitro</italic></article-title><source>Exp Biol Med (Maywood)</source><year>2007</year><volume>232</volume><fpage>1195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">17895527</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>EB</given-names></name><name><surname>Lowenstein</surname><given-names>EJ</given-names></name></person-group><article-title>Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero</article-title><source>Clin Dermatol</source><year>2011</year><volume>29</volume><fpage>652</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22014987</pub-id></element-citation></ref></ref-list></back></article>